Synapticure, a telemedicine company focused on neurodegenerative disease, announced it is partnering with the ALS Association to offer Synapticure’s telehealth platform as a supplement to in-person care at ALS Certified Treatment Centers of Excellence and Recognized Treatment Centers.
Synapticure is a neurology-focused telehealth company that specializes in neurodegenerative diseases. It provides treatment for conditions such as Alzheimer’s, Parkinson’s and ALS. It offers services that include mental health support, genetic testing and guidance related to clinical trials.
The partnership looks to address care inequities for people living with ALS in geographically remote areas who often lack access to specialized care. An ALS Association liaison will also be available through Synapticure’s virtual clinic to help provide personalized support to patients.
“Our mission at Synapticure is focused on providing state-of-the-art care regardless of geography. In partnership with the ALS Association, harnessing our combined national reach and deep expertise will enable us to revolutionize what it means to truly serve the ALS population. Working together, we will set a new standard of virtual care delivery,” Sandra Abrevaya, CEO and cofounder of Synapticure, said in a statement.
THE LARGER TREND
Synapticure launched in February of 2022 with $6 million in seed funding led by GV, a venture capital investment arm of Alphabet. Additional investment came from LifeForce Capital, Martin Ventures, Y-Combinator and Byers Capital.
In September of 2023, the Chicago-based company brought new CEO Joe Leinbach aboard. Leinbach was brought on as the company continued to expand neurodegenerative disease offerings, which now include ones for Alzheimer’s and Dementia.
In December of 2023, ALS Association partnered with virtual pulmonary-care company NuvoAir to launch a program tailored to people living with ALS. The partnership launched with two clinics in Texas at the Texas Neurology Center and University of Texas Health Science Center.
In February, ALS Association received a $58 million donation from philanthropist Hugh Hoffman. The gift is designated to advance ALS therapies and to develop new ALS clinics.
